IDEXX Laboratories Q1 2024 Adj EPS $2.81 Beats $2.67 Estimate, Sales $964.00M Miss $966.13M Estimate
Portfolio Pulse from Benzinga Newsdesk
IDEXX Laboratories (IDXX) reported Q1 2024 earnings of $2.81 per share, surpassing the $2.67 estimate, but sales of $964M missed the $966.13M forecast, marking a 7.09% year-over-year increase.
May 01, 2024 | 10:31 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
IDEXX Laboratories reported higher than expected Q1 2024 earnings per share but slightly missed sales estimates, with a year-over-year sales increase of 7.09%.
The positive earnings beat may provide a short-term uplift to IDXX's stock price due to investor optimism about profitability. However, the slight miss on sales estimates could temper gains, suggesting a neutral short-term impact. The year-over-year sales growth indicates underlying business strength, which could support investor confidence.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100